Clinical trials: Diabetes Type 1
Type 1 Diabetes Mellitus
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
Primary Objective: To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c).
- Trial name
- NCT03260868
- Testing
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Where
- 6 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.
- Trial name
- NCT02038764
- Testing
- PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Chronic Kidney Disease, Type 1 Diabetes Mellitus
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes.
- Trial name
- FINE-ONE (NCT05901831)
- Testing
- Finerenone
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 242 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 1
ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)
This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management…
- Trial name
- NCT02600845
- Testing
- ACCU-CHEK
- Where
- 11 sites in United States
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
- Trial name
- NCT01285518
- Testing
- PF-05231023
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
The purpose of this study is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose…
- Trial name
- TTEDD (NCT00451321)
- Testing
- Otelixizumab
- Where
- 17 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
This study will look at the treatment effect of DiaPep277 on preservation of beta-cell function, as defined by meal-stimulated secretion of insulin.
- Trial name
- DIA-AID2 (NCT01103284)
- Testing
- DiaPep277
- Where
- 75 sites in United States, Austria and 12 more
- Volunteers
- 475 people
- Sponsor
- Andromeda Biotech Ltd.
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion [CSII])…
- Trial name
- NCT01109316
- Testing
- Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Tandem Freedom - Feasibility Trial 2
This feasibility study is a prospective, single arm study evaluating the Tandem Freedom system in adults with type 1 diabetes. Existing Control-IQ technology users will use Control-IQ technology at home for a one week run-in…
- Trial name
- NCT06834568
- Testing
- t:slim X2 insulin pump with Tandem Freedom Algorithm
- Where
- New Zealand
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1
INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy
The aim of the project is to document the international routine practice in sensor usage in patients treated with sensor-augmented pump therapy and to assess which variables (e.g.
- Trial name
- NCT00790088
- Where
- 26 sites in Austria, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Immune Profile in Subjects With New Onset Type 1 Diabetes
It is hypothesized that early changes in the immune system in New Onset Type 1 Diabetes Mellitus (NOT1D) subjects can be detected in immune cells from the inguinal lymph nodes (iLN), which will be distinct from changes observed…
- Trial name
- NCT02801942
- Testing
- Inguinal lymph node fine needle aspirate biopsy, Inguinal lymph node core biopsy, Peripheral blood collection
- Where
- 2 sites in United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Diabetes Mellitus, Type 2
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- NCT01301456
- Testing
- PF-04856883
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Tandem Freedom Feasibility Study 1
This feasibility study is a prospective, single arm study evaluating the Tandem Freedom system in adults with type 1 diabetes. Existing Control-IQ technology users will use Control-IQ technology at home for a 1 week run-in, then…
- Trial name
- NCT06428591
- Testing
- t:slim X2 insulin pump with Tandem Freedom Algorithm
- Where
- New Zealand
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes, Diabetic Foot
Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care
This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard…
- Conditions
- Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT03626623
- Testing
- Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Integra LifeSciences Corporation
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar.
- Trial name
- NCT03341299
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study.
- Trial name
- NCT02402933
- Testing
- Nasal Glucagon
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
OPT101 in Type 1 Diabetes Patients
Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.
- Trial name
- NCT05428943
- Testing
- OPT101
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Op-T LLC
Type 1 Diabetes Mellitus
Use of the Guardian™ Connect System With Smart Connected Devices
The purpose of this study is to collect sensor, insulin, sleep, activity and food/meal data for a minimum of 90 days of device wear (Phase 1) and up to a maximum of 9 months of device wear (Phase 2) with optional insulin…
- Trial name
- NCT04809285
- Testing
- Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app
- Where
- 14 sites in United States
- Volunteers
- 217 people
- Sponsor
- Medtronic MiniMed, Inc.